Furthermore, NPB enhanced the efficacy of cisplatin in ovarian carcinoma and synergized with AZD5363, an AKT inhibitor in cisplatin resistant ovarian cancer [3]. This evidence concerns the gene AKT1 and ovarian carcinoma.